Novo Nordisk reported DKK96.82B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Bausch Health Companies USD 2.5B 300M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novo Nordisk DKK 96.82B 17.68B Mar/2026
Novo Nordisk DKK 12.53B 2.44B Dec/2025
Pacira USD 177M 19.87M Mar/2026
Sanofi EUR 11.24B 60M Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026